



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,184	09/24/2004	Alexander D Slowey	57666US005	7403

32692	7590	11/23/2009
3M INNOVATIVE PROPERTIES COMPANY		
PO BOX 33427		
ST. PAUL, MN 55133-3427		

EXAMINER	
ALSTRUM ACEVEDO, JAMES HENRY	

ART UNIT	PAPER NUMBER
1616	

NOTIFICATION DATE	DELIVERY MODE
11/23/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

LegalUSDocketing@mmm.com
LegalDocketing@mmm.com

Office Action Summary

Application No.

10/509,184

Applicant(s)

SLOWEY ET AL.

Examiner

JAMES H. ALSTRUM
ACEVEDO

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 September 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14 and 17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-14 and 17 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 1-14 and 17 are pending. Applicants cancelled claims 15-16. The decision of the Board of Patent Appeals and Interferences (BPAI) entered on September 2, 2009 is noted. The previous outstanding rejections of record are withdrawn per the BPAI decision reversing said rejections. The new art rejections below are similar to the rejections made in the related and commonly assigned application, 10/398,335 (now abandoned), which had been affirmed by the BPAI. Applicants are advised that a different Examiner is examining the instant application.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-14 and 17 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Determination of Claim Scope

Claims 1-14 and 17 of the instant application claim (1) a dispenser containing a pharmaceutical formulation comprising (a) formoterol or a pharmaceutically acceptable

Art Unit: 1616

salt, solvate, or physiologically functional derivative, (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, (c) a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or mixtures thereof, and (d) a bulking agent having a mass median diameter of less than one micron, wherein the interior surface of the aerosol vial is coated with a fluorocarbon polymer and (2) a method of making the formulation recited in claim 1 comprising (a) forming a slurry of the bulking agent with another formulation component, (b) homogenizing the slurry, and (c) combining the slurry with the remaining formulation components.

Review of Applicants' Disclosure

The instant specification does not disclose, to which solvates of formoterol or mometasone Applicants are referring to with the exception of formoterol fumarate dihydrate (i.e. a salt hydrate of formoterol). Applicants' specification does not disclose how to make any particular solvate or hydrate of formoterol or mometasone, nor do Applicants depict chemical structures of formoterol and mometasone as any particular hydrate or solvate in their disclosure.

Possession Based on Ordinary Skilled Artisan's Determination/ State of the Prior Art

It is generally accepted in the art that the formation of a particular solvate, polymorph, or hydrate for a given compound or series of compounds is unpredictable (see Vippagunta et al. "Crystalline Solids," *Advanced Drug Delivery Reviews*, **2001**, 48, 1-26, especially pp 1, 11-12, and 18), therefore, the generic reference to a solvate of either

Art Unit: 1616

formoterol and mometasone in the instant specification does not provide adequate written support for claims drawn to any solvate or hydrate of these compounds. It is noted that hydrates are a subgenus of solvates. Braga et al. (*Chem. Commun.*, "Making Crystals from Crystals: a green route to crystal engineering and polymorphism," **2005**, pp 3635-3645) states on page 3640, "One can say that if the formation of polymorphs is a nuisance for crystal engineers, solvate formation can be a nightmare, because it is extremely difficult to predict whether a new species may crystallize[s] from solution with one or more molecules of solvent." The state of the art is such that in this century **there should not be any doubt as to the chemical identity of a material** (Seddon, K.R., "Pseudopolymorph: a polemic," *Crystal Growth & Design*, **2004**, 4(6), pp 1087, web release date October 19, 2004). The only known solvate of mometasone found in the prior art is mometasone furoate monohydrate, which is known from WO 92/04265. Formoterol fumarate dihydrate is known from WO 01/78744 (IDS reference).

An ordinary skilled artisan would conclude that Applicants were not in possession of the genus of all possible known and unknown solvates or hydrates of formoterol and mometasone present in the claimed composition, with the exception of mometasone furoate monohydrate and formoterol fumarate dihydrate. Furthermore, because Applicants' generic reference to solvates or hydrates of formoterol and mometasone does not permit the ordinary skilled artisan to clearly envisage which specific solvates or hydrates of formoterol and mometasone were in Applicants' possession, aside from the two aforementioned exceptions, the only reasonable conclusion said artisan would make was that Applicants were not in possession of the genus of all known/unknown solvates hydrates of formoterol and mometasone and had not reduced to practice the preparation,

Art Unit: 1616

isolation, and characterization of said solvates and hydrates.

The remaining claims are rejected as depending from a rejected claim.

Claims 1-14 and 17 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for compositions comprising components (a)-(c) in the form of enantiomers, racemates, mixtures of enantiomers, and physiologically acceptable acid addition salts thereof, does not reasonably provide enablement for compositions comprising solvates or hydrates of any one or more of components (a)-(c). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

An analysis based upon the Wands factors is set forth below.

To be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In *Genentech Inc. v. Novo Nordisk* 108 F.3d 1361, 1365, 42 USPQ2d 1001, 1004 (Fed. Cir. 1997); *In re Wright* 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993),. See also *Amgen Inc. v. Chugai Pharm. Co.*, 927 F.2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed. Cir. 1991); *In re Fisher* 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). Further, in *In re Wands* 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) the court stated:

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman* (230 USPQ 546, 547 (Bd Pat App Int 1986)). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the

Art Unit: 1616

invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and (8) the breadth of the claims.

Breadth of Claims

Applicants' claims are broad with regards to the subgenera of solvates, hydrates, physiologically acceptable salts, and physiologically acceptable derivatives of formoterol and mometasone.

Nature of the invention/State of the Prior Art

Claims 1-14 and 17 of the instant application claim (1) a dispenser containing a pharmaceutical formulation comprising (a) formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, (c) a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or mixtures thereof, and (d) a bulking agent having a mass median diameter of less than one micron, wherein the interior surface of the aerosol vial is coated with a fluorocarbon polymer and (2) a method of making the formulation recited in claim 1 comprising (a) forming a slurry of the bulking agent with another formulation component, (b) homogenizing the slurry, and (c) combining the slurry with the remaining formulation components.

It is generally accepted in the art that the formation of a particular solvate or hydrate for a given compound or series of compounds is unpredictable (see Vippagunta et al. "Crystalline Solids," *Advanced Drug Delivery Reviews*, **2001**, 48, pp 11 and 18). Braga et al. (*Chem. Commun.*, "Making Crystals from Crystals: a green route to crystal

Art Unit: 1616

engineering and polymorphism,” **2005**, pp 3635-3645) states on page 3640, “One can say that if the formation of polymorphs is a nuisance for crystal engineers, solvate formation can be a nightmare, because it is extremely difficult to predict whether a new species may crystallize[s] from solution with one or more molecules of solvent.” The state of the art is such that in this century there should not be any doubt as to the chemical identity of a material (Seddon, K.R., “Pseudopolymorph: a polemic,” *Crystal Growth & Design*, **2004**, 4(6), pp 1087, web release date October 19, 2004).

Level of One of Ordinary Skill & Predictability/Unpredictability in the Art

The level of a person of ordinary skill in the art is high, with ordinary artisans having advanced medical and/or scientific degrees (e.g. M.D., Ph.D., Pharm. D. or combinations thereof). There is a general lack of predictability in the pharmaceutical art. *In re Fisher*, 427, F. 2d 833, 166, USPQ 18 (CCPA 1970). The art is especially unpredictable with regards to the existence and formation of particular polymorphs and pseudopolymorphs (e.g. hydrates and solvates) of chemical compounds, as set forth above by the teachings of Vippagunta et al. and Braga.

Guidance/Working Examples

Applicants provide no guidance or working examples about the preparation of any solvate or hydrate of any of formoterol and mometasone.

In conclusion, the specification, while being enabling for compositions comprising formoterol and mometasone in the form of the free base and physiologically acceptable salts thereof, does not reasonably provide enablement for compositions

Art Unit: 1616

comprising solvates or hydrates of formoterol and mometasone, with the exception of formoterol fumarate dihydrate and mometasone furoate monohydrate.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-14 and 17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 17 are indefinite, because said claim recite physiologically functional derivatives of formoterol and mometasone. In paragraph [0016] Applicants define the term "physiologically functional derivative" as meaning a chemical compound having the same physiological function as the parent compound, such as a compound that is convertible to formoterol or mometasone in the body. Applicants provide no guidance with regards to which chemical modifications to the core structure of formoterol and mometasone can be done without jeopardizing the physiological function of the resulting compound. Applicants' definition of "physiologically functional derivative" as applied to formoterol and mometasone does not shed light on the metes and bounds of the compounds encompassed by the term "physiologically functional derivative." Thus, an ordinary skilled artisan would not be apprised of the metes and bounds of "physiologically functional derivatives" of formoterol and mometasone.

The remaining claims are rejected as depending from a rejected claim.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Applicant Claims
2. Determining the scope and contents of the prior art.
3. Ascertaining the differences between the prior art and the claims at issue, and resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-14 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Oliver et al. (U.S. Patent No. 6,054,488) (IDS reference) in view of, Cutie (U.S. Patent No. 6,129,905) (IDS reference), Gavin et al. (WO 01/78740), and Ashurst et al. (U.S. Patent No. 6,131,566) (of record).

Applicant Claims

Applicants claim (1) a dispenser containing a pharmaceutical formulation comprising (a) formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, (c) a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or mixtures thereof, and (d) a bulking agent having a mass median diameter of less than one micron, wherein the interior surface of the aerosol vial is coated with a fluorocarbon polymer and (2) a method of making the formulation recited in claim 1 comprising (a) forming a slurry of the bulking agent with another formulation component, (b) homogenizing the slurry, and (c) combining the slurry with the remaining formulation components.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

Oliver teaches pharmaceutical suspension formulations comprising (i) 0.0025% to 0.1% w/w formoterol or an acid addition salt thereof, (ii) 0.1-5.0% w/w ethanol, (iii) a propellant comprising HFA 134a (i.e. 1,1,1,2-tetrafluoroethane), HFA 227 (i.e. 1,1,1,2,3,3,3-heptafluoroethane), or mixtures thereof, (iv) a micronized bulking agent (e.g. lactose) in a weight ratio of formoterol to bulking agent of from 1:3 to 1:100, and (v) a surfactant (title; abstract; col. 3, lines 5-42 and 45-59; and claims 1-19). Oliver teaches that the micronized bulking agent may prevent the drug from creaming by co-flocculating the drug (col. 3, lines 55-59). Suitable bulking agents include lactose, DL-alanine, ascorbic acid, glucose, D(+)-trehalose dihydrate, etc. (Id. at lines 52-55).

Art Unit: 1616

Formoterol is art-recognized as a long-acting beta-2 agonist that is suitable for metered dose inhaler formulations, is highly potent, and requires a considerably lower dosage than other drugs (col. 2, lines 51-55). The formulations are made in a glove box purged with dried air by (i) adding a small quantity of propellant to a pre-chilled stainless steel vessel, (ii) adding pre-chilled ethanol, (iii) slowly dispersing pre-chilled drug and/or bulking agent into the propellant/ethanol mixture to obtain a concentrate (i.e. preparing a slurry), (iv) adding a homogenizer to the concentrate vessel, (v) adding the concentrate to bulk propellant in a batching vessel, (vi) dispensing the formulation into pre-chilled aluminum cans, which are immediately sealed with a metering valve on each can (col. 4, lines 19-53). Oliver's method thus makes a dispenser fitted with a valve. The aluminum cans used in Oliver's method fairly read on vials.

Cutie teaches aerosol formulations containing (i) a sugar as a dispersant/diluent (i.e. bulking agent), (ii) a propellant (e.g. HFA 134a and/or HFA 227), and a suspended drug (e.g. salmeterol xinafoate, beclomethasone, etc.) (title; abstract; col. 3, lines 20-42; col. 4, lines 25-35; and claims 1-19). Mixtures of two or more drugs may be used (col. 4, lines 35-37). The sugar diluent/dispersant aids the incorporation of the dispersion in hydrocarbon and HFA propellants and provides many benefits, such as (i) facilitating the dispersion of the drug(s) and/or excipients, (ii) stabilizing the formulations, either physically, chemically, or both, (iii) facilitating transfer of the drug, (iv) facilitating the drug's micronization and/or deaggregation in vitro, (v) acting as a respiratory sensitizer or desensitizer of drug surface interactions at topical and/or mucosal surfaces, and (vi) acting as a density modifier (col. 4, lines 15-24). The particle size of the sugar should be no greater than 10 microns, preferably less than 5 microns in

Art Unit: 1616

diameter, most preferably substantially all of the particles should be less than about 2 microns in diameter and there is no lower limit on the particle size (col. 4, lines 62-67 and col. 5, lines 1-4).

Gavin teaches pharmaceutical aerosols suspension formulations comprising (i) an **anti-inflammatory steroid (i.e. mometasone furoate) or salt, solvate, or derivative thereof, (ii) a bronchodilator (i.e. salmeterol xinafoate) or salt, solvate, or derivative thereof, and (iii) a propellant (e.g. 1,1,1,2-tetrafluoroethane)**, which are suitable for the **treatment of respiratory disorders, such as asthma and COPD** (title; abstract; pg. 1, lines 1-6, 17-20, 25-34; pg. 2, line 30 through pg. 3, line 18; pg. 4, lines 4-7; Examples 1-3; pg. 8, lines 1-20; and claims 1-7). The formulations may comprise other therapeutic agents, such as other anti-inflammatories (e.g. fluticasone propionate, beclomethasone dipropionate, etc.), beta-2 adrenoreceptor agonists (i.e. betamimetic bronchodilators, such as, **formoterol**, etc.), anti-cholinergics, (e.g. tiotropium), etc. (pg. 5, line 33 through pg. 6, line 6). In Gavin's example 1, the exemplified formulation comprises 0.048% w/w salmeterol (i.e. a bronchodilator), 0.269% w/w mometasone furoate, and remainder 1,1,1,2-tetrafluoroethane.

Ashurst teaches that in some aerosol suspension formulations drugs (e.g. albuterol) adhere to the inner surfaces (e.g. can, valves, caps) of metered dose inhalers (col. 1, lines 51-58). The problem of drug adhesion is especially acute in hydrofluoroalkane propellant (e.g. P134a and P227, which are synonyms of HFA 134a and HFA 227) systems (Id. at 55-58). **The problem of drug adhesion is resolved by coating of the interior can surfaces with a fluorocarbon polymer** (col. 1, lines 59-63;

Art Unit: 1616

abstract; and claims 1, 37, and 47). Suitable fluorocarbon polymers and MDI can materials are disclosed by Ashurst at col. 4, line 32 through col. 5, line 29).

Regarding formoterol fumarate dihydrate, Applicants admit in paragraph [0006] of the specification of the instant application that this salt hydrate of formoterol is well-known, such as in WO 01/78744.

***Ascertainment of the Difference Between Scope the Prior Art and the Claims
(MPEP §2141.012)***

Oliver lacks the teaching of specific bulking agent particle size, formulations comprising mometasone in combination with a bronchodilator, and a dispenser having its interior surfaces coated with a fluorocarbon polymer. These deficiencies are cured by the teachings of Cutie, Gavin, and Ashurst, respectively.

***Finding of Prima Facie Obviousness Rationale and Motivation
(MPEP §2142-2143)***

It would have prima facie obvious at the time of the instant invention to utilize a bulking agent having a particle size of less than one micron, because both Cutie teaches that sugar bulking agents having a particle size of about 2 microns or less are suitable for ensuring the stability of pharmaceutical aerosol formulations comprising propellants, such as hydrofluorocarbons. An ordinary skilled artisan would have been motivated to utilize the particle sizes taught as being suitable by Cutie for the bulking agent in Oliver's formulations, because said particle sizes are taught as being suitable to obtain formulations that benefit from the benefits of the inclusion of a sugar bulking agent (e.g. greater formulation physical and chemical stability). An ordinary skilled artisan would

Art Unit: 1616

have had a reasonable expectation of successfully incorporating micronized bulking agents into Oliver's formulations, because Oliver teaches that the invented formulations require micronized bulking agent and Cutie teaches bulking agent particle sizes that promote the stability of pharmaceutical aerosol suspension formulation stability.

It would have *prima facie* obvious at the time of the instant invention to combine formoterol with mometasone, because both compounds are art-recognized as being suitable for the treatment of respiratory diseases such as asthma and COPD (Gavin). It is generally considered *prima facie* obvious to combine two compounds each of which is taught by the prior art to be useful for the same purpose, such as the treatment of asthma, in order to form a composition which is to be used for the very same purpose. The idea for combining them flows logically from their having been used individually in the prior art. See *In re Kerkhoven*, 626, F.2d 848, 205 USPQ 1069 (CCPA 1980). It is also noted that the combined prior art teaches/suggests the combination of two or more drugs (Gavin/Cutie). Thus, an ordinary skilled artisan would have had a reasonable expectation of successfully preparing aerosol suspension formulations comprising a mixture of formoterol and mometasone.

It would have *prima facie* obvious at the time of the instant invention to utilize a vial, such as an aluminum can, with its interior surfaces coated with a fluorocarbon propellant, because the prior art recognizes that pharmaceutical suspension formulations utilizing hydrofluorocarbon propellants are acutely susceptible to problems of drug adhesion to the inner surfaces of metered dose inhalers (e.g. can/vial surfaces, cap, valve surfaces, etc.) and the art recognizes that coating the inner surfaces of a MDI with fluorocarbon polymers is a means to solve the art-recognized problem (Ashurst). An

Art Unit: 1616

ordinary skilled artisan would thus have been motivated to coat the inner surfaces of a dispersing container (i.e. a MDI) with fluorocarbon polymers to reduce or prevent problems with drug adhesion and would have had a reasonable expectation of success, because the coating of the inner surfaces of MDI containers with fluorocarbon polymers is an art-recognized solution to the problem of drug adhesion in suspension aerosol hydrofluorocarbon propellant-based formulations.

Regarding claim 17, Oliver teaches the preparation of a slurry, homogenization of the slurry, and addition of the remaining formulation components. It is noted that the steps taught by Oliver are not in the same order as the steps recited in Applicants' claim 17. It is the Examiner's position that absent a showing of the criticality of the steps recited in Applicants' claim 17, it is prima facie obvious to modify the order of steps of a method. It is noted that Applicants' state that their formulations exhibited surprising little settling (i.e. creaming). This result is not considered surprising or unexpected, because the prior art (e.g. Cutie) recognized that the inclusion of sugar bulking agents having a particle size of less than about 2 microns enhanced suspension formulation stability (e.g. creaming was prevented and/or minimized). Specifically, regarding the bulking agent particle size recited in Applicants' claims, it is noted that the bulking agent particle size taught by the prior art substantially overlaps with the Applicants' recited bulking agent particle size. A prima facie case of obviousness necessarily exists when the prior art range overlaps or touches a claimed range, such as in the instant rejection. MPEP § 2144.05. Regarding formoterol fumarate dihydrate, Applicants admit in paragraph [0006] that this salt hydrate of formoterol is well-known. Regarding claims 5-6, assuming a density of ~ 1 g/ml for the resulting prior art propellant formulation while in

Art Unit: 1616

the MDI and a total volume of 100 mL, the concentration of formoterol would range from 0.025 mg/ml to 1 mg/ml (Oliver) and the concentration of mometasone would be 2.69 mg/mL (Gavin). Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because the combined teachings of the prior art is fairly suggestive of the claimed invention.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-14 and 17 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 39-61 of

Art Unit: 1616

copending Application No. 12/472,088 (copending '088) in view of Gavin et al. (WO 01/78740).

Applicants' claims 1 and 17 have been described above. Independent claim 39 of copending '088 claims a pharmaceutical aerosol formulation comprising (i) particles of drug dispersed (i.e. suspended), (ii) propellant, and (iii) a bulking agent having a mass median diameter of less than one micron. Dependent claim 42 of copending '088 further specifies that the bulking agent is lactose. Dependent claim 39 of copending '088 specifies that the drug may be selected from a group including formoterol.

The primary difference between the claims of the instant application and the claims of copending '088 are that the claims of copending '088 (1) do not specifically recite the combination of formoterol and mometasone and (2) do not recite a dispenser having its interior surfaces coated with a fluorocarbon polymer. These deficiencies are cured by the teachings of Gavin and Ashurst, which are set forth above. Regarding the limitations of the other dependent claims of the instant application and copending g'088, these limitations are substantially similar in both applications. Regarding formoterol fumarate dihydrate, Applicants have admitted in paragraph [0006] of their specification that this salt-hydrate of formoterol is well-known in the prior art. Therefore, a person of ordinary skill in the art at the time of the instant invention would have found claims 1-14 and 17 *prima facie* obvious over claims 39-61 of copending '088.

This is a provisional obviousness-type double patenting rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James H. Alstrum-Acevedo whose telephone number is

Art Unit: 1616

(571) 272-5548. The examiner is on a flexible schedule, but can normally be reached on M-F ~10am~5:30 pm, and Saturdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

J.H.A.-A.
Patent Examiner
Technology Center 1600

/Johann R. Richter/
Supervisory Patent Examiner, Art Unit 1616